UK inks deal with Pfizer and BioNTech for potential COVID-19 vaccines
Category: #health  By Pankaj Singh  Date: 2020-07-20
  • share
  • Twitter
  • Facebook
  • LinkedIn

UK inks deal with Pfizer and BioNTech for potential COVID-19 vaccines

Even though the COVID-19 vaccine hasn’t been launched worldwide, it seems that leading nations are competing over who will have first access once a vaccine is ready. Recently, the government of the UK has reportedly signed an agreement with Pfizer Inc. and BioNTech SE, leading pharmaceutical companies developing a vaccine against COVID-19, to supply 30 million doses of m-RNA based vaccine candidates being developed under BNT162 program.

Sources cite that the company’s experimental vaccine candidates are currently in development and are subject to regulatory approval. The terms and conditions of the deal were based on the volume of doses and timing of delivery.

For the record, the BNT162 program leverages BioNTech’s mRNA technology and is supported by Pfizer’s vaccine development and manufacturing capabilities. The vaccine candidates are currently undergoing clinical trials and not presently authorized for distribution across the world. Both companies are using pre-clinical and clinical data to decide the future course of vaccine development.

Also, both companies are currently evaluating the minimum four potential vaccines, each of which represents a unique combination of mRNA format and target antigen. BioNTech and Pfizer previously announced the preliminary outcomes from BNT162b1, the most advanced mRNA formulations.

The data showed that BNT162b1 can produce neutralizing antibodies in humans at or above the levels detected in the plasma from COVID-19 recovered patients at relatively low dose levels.

Both companies are planning to commence Phase 2b/3 efficiency and safety trials later this month. If studies are successful, Pfizer and BioNTech will seek Conditional Marketing Authorization and regulatory review until October 2020. Both companies aim to produce up to 100 mn doses by 2020 and over 1.3 bn doses by the end of 2021.

For the record, SARC-COV-2 has infected over 14 million and took the lives of 0.8 million people across the globe, and the effective vaccine seems to be the only way that can put an end on the pandemic.

Source - https://www.businesswire.com/news/home/20200719005057/en/Pfizer-BioNTech-Announce-Agreement-United-Kingdom-30



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Supemtek® influenza vaccine gains approval in European Union
Supemtek® influenza vaccine gains approval in European Union
By Pankaj Singh

The European Commission has recently approved the authorization for commercialization of Supemtek®, a quadrivalent recombinant technology-based influenza vaccine, designed for preventing influenza among ...

Zymeworks, ALX Oncology to evaluate zanidatamab-ALX148 combination
Zymeworks, ALX Oncology to evaluate zanidatamab-ALX148 combination
By Pankaj Singh

Zymeworks Inc., a clinical-stage biopharmaceutical company involved in developing multifunctional biotherapeutics has recently entered into a clinical collaboration with ALX Oncology Holdings Inc., a clinical-stage imm...

DW Healthcare Partners invests in virtual care provider CareXM
DW Healthcare Partners invests in virtual care provider CareXM
By Pankaj Singh

Healthcare focused private equity firm, DW Healthcare Partners, has reportedly shared plans to partner with virtual care and patient engagement solutions provider, CareXM. The deal represents one of the three investmen...